Bevacizumab vs Jobevne (bevacizumab-nwgd)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
Bevacizumab
Marketed by Roche
NCT00806923 · Phase 3 · completed
This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: November 2026 · NCT04958811 (registry estimate)
Reported efficacy
Progression-free survival (Event driven): Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo (met)
Result source: NCT00806923
Jobevne (bevacizumab-nwgd)
Marketed by Biocon and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bevacizumab | Jobevne (bevacizumab-nwgd) |
|---|---|---|
| PFS, median | 4.8 vs 3.7+1.1 vs placeboNCT0025760817 other results
| —Not reported |
| OS, median | 9.3 vs 9.2+0.1 vs placeboNCT0013072820 other results
| —Not reported |
| ORR | 47.6% vs 42.8%vs Bevacizumab (Avastin)NCT027548829 other results
| —Not reported |
| Duration of response, median | 9.7 vs 8.4+1.3 vs placeboNCT001307284 other results
| —Not reported |
PFS, median
- Bevacizumab
- 4.8 vs 3.7+1.1 vs placeboNCT00257608
17 other results
- 4.8 NCT00976456
- 6.8 NCT00976456
- 3.4 vs 1.7 NCT00130728
- 8.3 vs 8.6 NCT03296163
- 7.7 vs 7.6 NCT02810457
- 8.4 vs 8.3 NCT02954172
- 6.0 vs 5.5 NCT00762034
- 15.4 NCT03133546
- 12.3 NCT03133546
- 13.5 NCT01532089
- 17.9 NCT01532089
- 7.9 NCT00271505
- 8.5 NCT00655850
- 2.8 NCT04426825
- 2.8 NCT04426825
- 14.9 NCT00828009
- 7.2 NCT00227019
- Jobevne (bevacizumab-nwgd)
- —Not reported
OS, median
- Bevacizumab
- 9.3 vs 9.2+0.1 vs placeboNCT00130728
20 other results
- 85.8 NCT00324805
- 19.2 vs 14.7 NCT02366143
- 19 vs 14.7 NCT02366143
- 11.9 vs 10.2 NCT01351415
- 12.6 vs 13.4 NCT00762034
- 14.4 vs 13.3 NCT00257608
- 14.1 vs 16.9 NCT02810457
- 18.0 NCT02954172
- 11.6 NCT00976456
- 14.4 NCT00976456
- 14.6 NCT00451906
- 24 NCT03133546
- 24.3 NCT03133546
- 14.1 NCT04426825
- 50.6 NCT01532089
- 32.4 NCT01532089
- 42.7 NCT00828009
- 16.5 NCT00271505
- 14.8 NCT00227019
- 25.5 NCT00655850
- Jobevne (bevacizumab-nwgd)
- —Not reported
ORR
- Bevacizumab
- 47.6% vs 42.8%vs Bevacizumab (Avastin)NCT02754882
9 other results
- 40.3% vs 44.6% NCT03296163
- 44.3% vs 46.4% NCT02954172
- 51.6% vs 53.7% NCT02810457
- 12.6% vs 6.2% NCT00130728
- 47.8% vs 51% NCT02810457
- 8.6% vs 6.3% NCT01351415
- 34.1% vs 33% NCT00762034
- 18.2% NCT04426825
- 17.4% NCT04426825
- Jobevne (bevacizumab-nwgd)
- —Not reported
Duration of response, median
- Bevacizumab
- 9.7 vs 8.4+1.3 vs placeboNCT00130728
4 other results
- 6.5 vs 6.3 NCT02810457
- 7.5 vs 6.2 NCT01351415
- 6.4 NCT04426825
- 6.4 NCT04426825
- Jobevne (bevacizumab-nwgd)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Jobevne (bevacizumab-nwgd): no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bevacizumab: 4 of 4 rows · Jobevne (bevacizumab-nwgd): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bevacizumab |
|---|---|
| Dropout rate | 99.4%a NCT00451906 · Phase 4 · registry result, not featured evidence · combination show 31 more results64.2% NCT00324805 · Phase 3 · registry result, not featured evidence · combination 89.8% NCT02810457 · Phase 3 · registry result, not featured evidence —Arm A (Atezo+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 34.3% NCT03296163 · Phase 3 · registry result, not featured evidence 82.1% NCT00130728 · Phase 3 · registry result, not featured evidence · combination 1.3% NCT02954172 · Phase 3 · registry result, not featured evidence · combination 90.8% NCT02754882 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT01351415 · Phase 3 · registry result, not featured evidence · combination 37.7% NCT00762034 · Phase 3 · registry result, not featured evidence · combination — NCT00257608 · Phase 3 · registry result, not featured evidence · combination 31.9%Bevacizumab + Pemetrexed NCT00976456 · Phase 3 · registry result, not featured evidence · combination 27.9%Bevacizumab + Pemetrexed + Carbopl NCT00976456 · Phase 3 · registry result, not featured evidence · combination 0% NCT01661790 · Phase 3 · registry result, not featured evidence · combination —Bevacizumab +Pemetrexed Maintenanc NCT00961415 · Phase 3 · registry result, not featured evidence · combination —Maintenance Treatment Arm A NCT00961415 · Phase 3 · registry result, not featured evidence —Maintenance Treatment Arm B NCT00961415 · Phase 3 · registry result, not featured evidence · combination 64.9%Osimertinib Alone NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy 65.4%Osimertinib Plus Bevacizumab NCT03133546 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04426825 · Phase 2 · registry result, not featured evidence · combination 0%Arm A (Erlotinib Hydrochloride) NCT01532089 · Phase 2 · registry result, not featured evidence 0%Arm B (Erlotinib Hydrochloride, Be NCT01532089 · Phase 2 · registry result, not featured evidence · combination 100%10 mg/kg + mFOLFOX6 ± Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination 100%5 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence 100%3 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence 100%2 mg/kg + mFOLFOX6 + Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination 100%0.45 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence — NCT00828009 · Phase 2 · registry result, not featured evidence — NCT00271505 · Phase 2 · registry result, not featured evidence · combination 0% NCT00227019 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT00655850 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 22.9%a NCT00451906 · Phase 4 · registry result, not featured evidence · combination show 31 more results27% NCT00324805 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT02810457 · Phase 3 · registry result, not featured evidence —Arm A (Atezo+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 —Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 — NCT03296163 · Phase 3 · registry result, not featured evidence — NCT00130728 · Phase 3 · registry result, not featured evidence · combination — NCT02954172 · Phase 3 · registry result, not featured evidence · combination — NCT02754882 · Phase 3 · registry result, not featured evidence — NCT01351415 · Phase 3 · registry result, not featured evidence · combination 5.7% NCT00762034 · Phase 3 · registry result, not featured evidence · combination — NCT00257608 · Phase 3 · registry result, not featured evidence · combination 12.6%Bevacizumab + Pemetrexed NCT00976456 · Phase 3 · registry result, not featured evidence · combination 16.2%Bevacizumab + Pemetrexed + Carbopl NCT00976456 · Phase 3 · registry result, not featured evidence · combination — NCT01661790 · Phase 3 · registry result, not featured evidence · combination —Bevacizumab +Pemetrexed Maintenanc NCT00961415 · Phase 3 · registry result, not featured evidence · combination —Maintenance Treatment Arm A NCT00961415 · Phase 3 · registry result, not featured evidence —Maintenance Treatment Arm B NCT00961415 · Phase 3 · registry result, not featured evidence · combination —Osimertinib Alone NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy —Osimertinib Plus Bevacizumab NCT03133546 · Phase 2 · registry result, not featured evidence · combination — NCT04426825 · Phase 2 · registry result, not featured evidence · combination —Arm A (Erlotinib Hydrochloride) NCT01532089 · Phase 2 · registry result, not featured evidence —Arm B (Erlotinib Hydrochloride, Be NCT01532089 · Phase 2 · registry result, not featured evidence · combination —10 mg/kg + mFOLFOX6 ± Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination —5 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence —3 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence —2 mg/kg + mFOLFOX6 + Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination —0.45 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence — NCT00828009 · Phase 2 · registry result, not featured evidence — NCT00271505 · Phase 2 · registry result, not featured evidence · combination — NCT00227019 · Phase 2 · registry result, not featured evidence · combination — NCT00655850 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 37.7%a NCT00451906 · Phase 4 · registry result, not featured evidence · combination show 31 more results76.6% NCT00324805 · Phase 3 · registry result, not featured evidence · combination 25.1% NCT02810457 · Phase 3 · registry result, not featured evidence 42.5%Arm A (Atezo+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 48.3%Arm B (Atezo+Bev+CP) NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 18.6% NCT03296163 · Phase 3 · registry result, not featured evidence 46.6% NCT00130728 · Phase 3 · registry result, not featured evidence · combination 33.5% NCT02954172 · Phase 3 · registry result, not featured evidence · combination 19.8% NCT02754882 · Phase 3 · registry result, not featured evidence 51.9% NCT01351415 · Phase 3 · registry result, not featured evidence · combination 42.5% NCT00762034 · Phase 3 · registry result, not featured evidence · combination 23.4% NCT00257608 · Phase 3 · registry result, not featured evidence · combination 6.7%Bevacizumab + Pemetrexed NCT00976456 · Phase 3 · registry result, not featured evidence · combination 5.2%Bevacizumab + Pemetrexed + Carbopl NCT00976456 · Phase 3 · registry result, not featured evidence · combination 0% NCT01661790 · Phase 3 · registry result, not featured evidence · combination —Bevacizumab +Pemetrexed Maintenanc NCT00961415 · Phase 3 · registry result, not featured evidence · combination 21.7%Maintenance Treatment Arm A NCT00961415 · Phase 3 · registry result, not featured evidence 33.6%Maintenance Treatment Arm B NCT00961415 · Phase 3 · registry result, not featured evidence · combination 35.1%Osimertinib Alone NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy 43.4%Osimertinib Plus Bevacizumab NCT03133546 · Phase 2 · registry result, not featured evidence · combination 17.4% NCT04426825 · Phase 2 · registry result, not featured evidence · combination 26.7%Arm A (Erlotinib Hydrochloride) NCT01532089 · Phase 2 · registry result, not featured evidence 39.5%Arm B (Erlotinib Hydrochloride, Be NCT01532089 · Phase 2 · registry result, not featured evidence · combination 100%10 mg/kg + mFOLFOX6 ± Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination 0%5 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence 100%3 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence 50%2 mg/kg + mFOLFOX6 + Bevacizumab NCT01327612 · Phase 2 · registry result, not featured evidence · combination 0%0.45 mg/kg NCT01327612 · Phase 2 · registry result, not featured evidence 33.3% NCT00828009 · Phase 2 · registry result, not featured evidence 32.5% NCT00271505 · Phase 2 · registry result, not featured evidence · combination 50% NCT00227019 · Phase 2 · registry result, not featured evidence · combination 69.4% NCT00655850 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a fatigue 40.4% nausea 37.4% haemoglobin decreased 35.6% NCT00451906 · Phase 4 · registry result, not featured evidence · combination show 30 more resultscreatinine increased 33.6% neutrophil count decreased 32.1% anemia 24.9% NCT00324805 · Phase 3 · registry result, not featured evidence · combination alopecia 42.5% neutropenia 30.1% anaemia 29% NCT02810457 · Phase 3 · registry result, not featured evidence alopecia 45% anaemia 36.5% nausea 32.5% NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 alopecia 47.8% nausea 37.9% fatigue 34.9% NCT02366143 · Phase 3 · registry result, not featured evidence · combination · Non-Small Cell Lung Cancer · phase 3 alopecia 49.8% anemia 32.5% nausea 15.1% NCT03296163 · Phase 3 · registry result, not featured evidence diarrhoea 64.9% (placebo 51.8%) rash 61.7% (placebo 58.8%) fatigue 46.6% (placebo 39.6%) NCT00130728 · Phase 3 · registry result, not featured evidence · combination white blood cell count decreased 71.9% neutrophil count decreased 70.5% platelet count decreased 50.4% NCT02954172 · Phase 3 · registry result, not featured evidence · combination diarrhoea 37% nausea 34.6% decreased appetite 34.2% NCT01351415 · Phase 3 · registry result, not featured evidence · combination fatigue 60.6% nausea 53.4% constipation 41% NCT00762034 · Phase 3 · registry result, not featured evidence · combination rash 55.4% (placebo 18.8%) diarrhoea 51.1% (placebo 19.6%) fatigue 34.2% (placebo 24.8%) NCT00257608 · Phase 3 · registry result, not featured evidence · combination anaemia 51.3% NCT00976456 · Phase 3 · registry result, not featured evidence · combination anaemia 72.4% NCT00976456 · Phase 3 · registry result, not featured evidence · combination leucocytopenia 66.7% NCT01661790 · Phase 3 · registry result, not featured evidence · combination nausea 60.8% hypertension 35.8% asthenia 35% NCT00961415 · Phase 3 · registry result, not featured evidence nausea 61.6% hypertension 44% fatigue 32% NCT00961415 · Phase 3 · registry result, not featured evidence · combination diarrhea 49.4% fatigue 37.7% cough 36.4% NCT03133546 · Phase 2 · registry result, not featured evidence · monotherapy diarrhea 53.9% proteinuria 48.7% fatigue 43.4% NCT03133546 · Phase 2 · registry result, not featured evidence · combination proteinuria 30.4% aspartate aminotransferase increased 26.1% fatigue 26.1% NCT04426825 · Phase 2 · registry result, not featured evidence · combination rash acneiform 88.9% diarrhea 82.2% hypertension 51.1% NCT01532089 · Phase 2 · registry result, not featured evidence rash acneiform 97.7% diarrhea 88.4% hypertension 83.7% NCT01532089 · Phase 2 · registry result, not featured evidence · combination 10 mg/kg + mFOLFOX6 ± Bevacizumab abdominal pain 66.7% amylase increased 66.7% anaemia 66.7% NCT01327612 · Phase 2 · registry result, not featured evidence · combination 5 mg/kg back pain 100% blood creatinine increased 100% blood phosphorus increased 100% NCT01327612 · Phase 2 · registry result, not featured evidence 3 mg/kg hepatic enzyme increased 100% hepatitis c 100% oesophageal carcinoma 100% NCT01327612 · Phase 2 · registry result, not featured evidence 2 mg/kg + mFOLFOX6 + Bevacizumab diarrhoea 100% fatigue 100% neutropenia 100% NCT01327612 · Phase 2 · registry result, not featured evidence · combination 0.45 mg/kg chest x-ray abnormal 100% cough 100% herpes zoster 100% NCT01327612 · Phase 2 · registry result, not featured evidence fatigue 78.8% anemia 54.5% peripheral sensory neuropathy 51.5% NCT00828009 · Phase 2 · registry result, not featured evidence alopecia 62.5% fatigue 52.5% hyperglycemia 52.5% NCT00271505 · Phase 2 · registry result, not featured evidence · combination pain 75% fatigue 68.8% anorexia 50% NCT00227019 · Phase 2 · registry result, not featured evidence · combination fatigue: induction 88.9% hypertension grade: end of induction 88.9% anemia: induction 75% NCT00655850 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bevacizumab
show 11 more results
show 9 more results
show 7 more results
show 5 more results
show 2 more results
show 1 more result
show 1 more result
+ 33 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bevacizumab's landscape · Jobevne (bevacizumab-nwgd)'s landscape